Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study

Mauro Moroni, Silvio Veronese, Silvia Benvenuti, Giovanna Marrapese, Andrea Sartore-Bianchi, Federica Di Nicolantonio, Marcello Gambacorta, Salvatore Siena, Alberto Bardelli

Research output: Contribution to journalArticle

848 Citations (Scopus)

Abstract

Background: The antiepidermal growth factor receptor (antiEGFR) monoclonal antibodies cetuximab and panitumumab have good clinical activity in about 10% of patients with metastatic colorectal cancer that is resistant to chemotherapy. The molecular mechanisms underlying clinical response or resistance to these agents are unknown. Methods: Tumours from 31 patients with metastatic colorectal cancer who had either an objective response (n=10) or stable disease or progressive disease (n=21) after treatment with cetuximab or panitumumab were screened for genetic changes in EGFR or its immediate intracellular effectors. Specifically, we assessed the EGFR copy number and the mutation profile of the EGFR catalytic domain and of selected exons in KRAS, BRAF, and PIK3CA. Results: Eight of nine of patients with objective responses who were assessable by fluorescence in-situ hybridisation (FISH) had an increased EGFR copy number. By contrast, one of 21 non-responders assessable by FISH had an increased EGFR copy number (p

Original languageEnglish
Pages (from-to)279-286
Number of pages8
JournalThe Lancet Oncology
Volume6
Issue number5
DOIs
Publication statusPublished - May 2005

Fingerprint

Gene Dosage
Growth Factor Receptors
Epidermal Growth Factor Receptor
Colorectal Neoplasms
Cohort Studies
Fluorescence In Situ Hybridization
Therapeutics
Exons
Catalytic Domain
Monoclonal Antibodies
Drug Therapy
Mutation
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer : A cohort study. / Moroni, Mauro; Veronese, Silvio; Benvenuti, Silvia; Marrapese, Giovanna; Sartore-Bianchi, Andrea; Di Nicolantonio, Federica; Gambacorta, Marcello; Siena, Salvatore; Bardelli, Alberto.

In: The Lancet Oncology, Vol. 6, No. 5, 05.2005, p. 279-286.

Research output: Contribution to journalArticle

Moroni, Mauro ; Veronese, Silvio ; Benvenuti, Silvia ; Marrapese, Giovanna ; Sartore-Bianchi, Andrea ; Di Nicolantonio, Federica ; Gambacorta, Marcello ; Siena, Salvatore ; Bardelli, Alberto. / Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer : A cohort study. In: The Lancet Oncology. 2005 ; Vol. 6, No. 5. pp. 279-286.
@article{d42668578baf46ff9debc1d3a4390cbd,
title = "Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study",
abstract = "Background: The antiepidermal growth factor receptor (antiEGFR) monoclonal antibodies cetuximab and panitumumab have good clinical activity in about 10{\%} of patients with metastatic colorectal cancer that is resistant to chemotherapy. The molecular mechanisms underlying clinical response or resistance to these agents are unknown. Methods: Tumours from 31 patients with metastatic colorectal cancer who had either an objective response (n=10) or stable disease or progressive disease (n=21) after treatment with cetuximab or panitumumab were screened for genetic changes in EGFR or its immediate intracellular effectors. Specifically, we assessed the EGFR copy number and the mutation profile of the EGFR catalytic domain and of selected exons in KRAS, BRAF, and PIK3CA. Results: Eight of nine of patients with objective responses who were assessable by fluorescence in-situ hybridisation (FISH) had an increased EGFR copy number. By contrast, one of 21 non-responders assessable by FISH had an increased EGFR copy number (p",
author = "Mauro Moroni and Silvio Veronese and Silvia Benvenuti and Giovanna Marrapese and Andrea Sartore-Bianchi and {Di Nicolantonio}, Federica and Marcello Gambacorta and Salvatore Siena and Alberto Bardelli",
year = "2005",
month = "5",
doi = "10.1016/S1470-2045(05)70102-9",
language = "English",
volume = "6",
pages = "279--286",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "5",

}

TY - JOUR

T1 - Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer

T2 - A cohort study

AU - Moroni, Mauro

AU - Veronese, Silvio

AU - Benvenuti, Silvia

AU - Marrapese, Giovanna

AU - Sartore-Bianchi, Andrea

AU - Di Nicolantonio, Federica

AU - Gambacorta, Marcello

AU - Siena, Salvatore

AU - Bardelli, Alberto

PY - 2005/5

Y1 - 2005/5

N2 - Background: The antiepidermal growth factor receptor (antiEGFR) monoclonal antibodies cetuximab and panitumumab have good clinical activity in about 10% of patients with metastatic colorectal cancer that is resistant to chemotherapy. The molecular mechanisms underlying clinical response or resistance to these agents are unknown. Methods: Tumours from 31 patients with metastatic colorectal cancer who had either an objective response (n=10) or stable disease or progressive disease (n=21) after treatment with cetuximab or panitumumab were screened for genetic changes in EGFR or its immediate intracellular effectors. Specifically, we assessed the EGFR copy number and the mutation profile of the EGFR catalytic domain and of selected exons in KRAS, BRAF, and PIK3CA. Results: Eight of nine of patients with objective responses who were assessable by fluorescence in-situ hybridisation (FISH) had an increased EGFR copy number. By contrast, one of 21 non-responders assessable by FISH had an increased EGFR copy number (p

AB - Background: The antiepidermal growth factor receptor (antiEGFR) monoclonal antibodies cetuximab and panitumumab have good clinical activity in about 10% of patients with metastatic colorectal cancer that is resistant to chemotherapy. The molecular mechanisms underlying clinical response or resistance to these agents are unknown. Methods: Tumours from 31 patients with metastatic colorectal cancer who had either an objective response (n=10) or stable disease or progressive disease (n=21) after treatment with cetuximab or panitumumab were screened for genetic changes in EGFR or its immediate intracellular effectors. Specifically, we assessed the EGFR copy number and the mutation profile of the EGFR catalytic domain and of selected exons in KRAS, BRAF, and PIK3CA. Results: Eight of nine of patients with objective responses who were assessable by fluorescence in-situ hybridisation (FISH) had an increased EGFR copy number. By contrast, one of 21 non-responders assessable by FISH had an increased EGFR copy number (p

UR - http://www.scopus.com/inward/record.url?scp=17844362179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844362179&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(05)70102-9

DO - 10.1016/S1470-2045(05)70102-9

M3 - Article

C2 - 15863375

AN - SCOPUS:17844362179

VL - 6

SP - 279

EP - 286

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 5

ER -